Søgning på udtrykket 'tixagevimab' giver 14 resultater


Nyt fra tidsskrifterne [13] Aktuelle smitsomme sygdomme [1]

Nyt fra tidsskrifterne [13]

Clinical Microbiology and Infection
31.07.2022
Immunocompromised patients have an increased risk of severe form of COVID-19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as pre-exposure prophylaxis against BA.1 and BA.2 SARS-CoV-2 Omicron sublineages is unknown. We aimed to describe the incidence and outcomes of COVID-19 among immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis, during the Omicron wave in France.
Lancet Respiratory Medicine
9.07.2022
Among patients hospitalised with COVID-19 receiving remdesivir and other standard care, tixagevimab–cilgavimab did not improve the primary outcome of time to sustained recovery but was safe and mortality was lower.
Lancet Respiratory Medicine
8.06.2022
A single intramuscular tixagevimab–cilgavimab dose provided statistically and clinically significant protection against progression to severe COVID-19 or death versus placebo in unvaccinated individuals and safety was favourable. Treating mild to moderate COVID-19 earlier in the disease course with tixagevimab–cilgavimab might lead to more favourable outcomes.
New England Journal of Medicine
20.04.2022
New England Journal of Medicine, Ahead of Print.
Journal of the American Medical Association
25.01.2022
This Medical Letter review summarizes the use of tixagevimab and cilgavimab (Evusheld), investigational long-acting monoclonal antibodies to be administered concomitantly by intramuscular injection for preexposure prophylaxis of COVID-19 in persons aged 12 years or older.
Journal of the American Medical Association
20.09.2022
This JAMA Patient Page describes the combination medication tixagevimab-cilgavimab, which is used to help prevent COVID-19 infection in people with immunosuppression or who have had a COVID-19 vaccine reaction.
Journal of the American Medical Association
16.08.2022
People eligible for COVID-19 preexposure prophylaxis (PrEP) with the monoclonal antibody combination of tixagevimab and cilgavimab (Evusheld) should be treated every 6 months to maintain protection against infection, according to the recently revised Fact Sheet for Healthcare Providers.
Clinical Microbiology and Infection
31.07.2022
Immunocompromised patients have an increased risk of severe form of COVID-19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as pre-exposure prophylaxis against BA.1 and BA.2 SARS-CoV-2 Omicron sublineages is unknown. We aimed to describe the incidence and outcomes of COVID-19 among immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis, during the Omicron wave in France.
Journal of the American Medical Association
26.07.2022
Tixagevimab plus cilgavimab, a SARS-CoV-2–neutralizing monoclonal antibody combination marketed as Evusheld, protected nonhospitalized individuals with mild to moderate COVID-19 symptoms from progressing to severe COVID-19 or death in a clinical trial. The study, published in The Lancet Respiratory Medicine, is the first to evaluate the intramuscular injection for outpatient treatment; other anti–SARS-CoV-2 monoclonal antibodies must be administered intravenously or subcutaneously.
Lancet Respiratory Medicine
9.07.2022
… patients who are hospitalised are mixed.4–8 In The Lancet Respiratory Medicine, Thomas L Holland and colleagues present results of the ACTIV-3 trial comparing intravenous tixagevimab−cilgavimab with placebo for patients hospitalised with COVID-19.8 Although tixagevimab−cilgavimab did not improve the primary outcome of time to sustained recovery (rate ratio [RR] 1·08 [95% CI 0·97–1·20]; p=0·21), it was associated with improved 28-day (6% vs 9%; p=0·02) and 90-day (9% vs 12%; p=0·03) mortality.
Lancet Respiratory Medicine
9.07.2022
Among patients hospitalised with COVID-19 receiving remdesivir and other standard care, tixagevimab–cilgavimab did not improve the primary outcome of time to sustained recovery but was safe and mortality was lower.
Lancet Respiratory Medicine
8.06.2022
A single intramuscular tixagevimab–cilgavimab dose provided statistically and clinically significant protection against progression to severe COVID-19 or death versus placebo in unvaccinated individuals and safety was favourable. Treating mild to moderate COVID-19 earlier in the disease course with tixagevimab–cilgavimab might lead to more favourable outcomes.
Journal of the American Medical Association
25.01.2022
This Medical Letter review summarizes the use of tixagevimab and cilgavimab (Evusheld), investigational long-acting monoclonal antibodies to be administered concomitantly by intramuscular injection for preexposure prophylaxis of COVID-19 in persons aged 12 years or older.

Aktuelle smitsomme sygdomme [1]

Medscape Infectious Diseases
1.10.2021
Two long-acting antibodies — tixagevimab mixed with cilgavimab — reduced the risk of developing symptomatic COVID by 77% in a phase 3 trial of adults at high risk of contracting the virus.

Nyhedsbrev

Skriv din email adresse og modtag nyheder om hjemmesiden.


© 2022 Dansk Selskab for Infektionsmedicin

CVR: 33634307

version: 2.11.0 ● design: Christian Philip Fischer

Side indlæst på 0,607 s

Cookies og privatliv